Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Defining Outcomes in Hispanic Aggressive Non-Hodgkin Lymphoma Patients.

Lara M Paraskos, M.D., Mariela A. Blum, MD, Maricer Escalon, MD, Annapoorna Ferrell, Erin Kobetz, Joseph Rosenblatt, MD

Blood (2009) 114 (22): 4542.

https://doi.org/10.1182/blood.V114.22.4542.4542

Published: 2009

Journal Articles

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

Michelle Fanale, MD, Nancy L Bartlett, MD, Andres Forero-Torres, MD, Joseph Rosenblatt, MD, Sandra J Horning, MD, Anna R Franklin, MD, Carmel M Lynch, PhD, Eric L Sievers, MD, Dana A Kennedy, PharmD, BCOP

Blood (2009) 114 (22): 2731.

https://doi.org/10.1182/blood.V114.22.2731.2731

Published: 2009

Journal Articles

B Cell Depletion Reduces the Number and Function of T- Regulatory Cells and Enhances the Anti Tumor response

Tamar Tadmor, MD, Yu Zhang, MD, Robert Dunn, PHD, Seung-uon Shin, Hyung-Mee Cho, Joseph Rosenblatt, MD

Blood (2009) 114 (22): 3668.

https://doi.org/10.1182/blood.V114.22.3668.3668

Published: 2009

Journal Articles

High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T

Peter J Hosein, MD, Daniel Morgensztern, MD, Francine Coleman, MPH, Gail Walker, PhD, Maricer Escalon, MD, Joseph Rosenblatt, MD, Izidore S Lossos, MD

Blood (2008) 112 (11): 3597.

https://doi.org/10.1182/blood.V112.11.3597.3597

Published: 2008

Journal Articles

Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.

Izidore S. Lossos, MD, Francine Colleman, Gail Walker, Maricer Escalon, MD, Joseph Rosenblatt, MD, Daniel Morgensztern, MD

Blood (2007) 110 (11): 1363.

https://doi.org/10.1182/blood.V110.11.1363.1363

Published: 2007

NARROW

Defining Outcomes in Hispanic Aggressive Non-Hodgkin Lymphoma Patients.

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

B Cell Depletion Reduces the Number and Function of T- Regulatory Cells and Enhances the Anti Tumor response

High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T

Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Defining Outcomes in Hispanic Aggressive Non-Hodgkin Lymphoma Patients.

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

B Cell Depletion Reduces the Number and Function of T- Regulatory Cells and Enhances the Anti Tumor response

High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T

Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only